
From:
Sent: 10 September 2008 10:34
To:
Cc:
Subject: Re: Appeal on Final Appraisal Determination – Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF- α inhibitor

NHS
**National Institute for
Health and Clinical Excellence**

Midcity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

Sent via email

www.nice.org.uk

Dear

Re: Appeal on Final Appraisal Determination – Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF- α inhibitor

Thank you for your notice dated 4 September. This letter represents my final decision on the initial validity of the appeal points you have raised.

With the exception of your ground at paras 3.1-3.5 I agree all of your points are valid. There may have been some confusion over paragraphs 3.1-3.5 from my earlier letter, where I was suggesting that this appeal point should be moved from ground one to ground two, not brought under both grounds. I can confirm that I consider it to be valid under ground two but not valid under ground one.

Yours sincerely

Mark Taylor
Appeals Committee Chair
National Institute for Health and Clinical Excellence

23/09/2008